Status:
UNKNOWN
Role of Tofacitinib in Vitiligo Patients
Lead Sponsor:
Pi Research Consultancy Center, Bangladesh
Conditions:
Vitiligo
Effect of Drug
Eligibility:
All Genders
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
Standard treatment for vitiligo often has unsatisfactory outcomes. With a new understanding of pathogenesis, novel drugs have been introduced which have shown to be effective in small-scale studies. T...
Detailed Description
Participant selection: All vitiligo irrespective of the duration of the disease presenting at the outpatient department will be initially approached for inclusion in the study. Eighty patients who wi...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Vitiligo patients
- Willing to participate
Exclusion
- Age \<18 years
- Patients with leukoderma secondary to other causes
- Participants with segmental or universal vitiligo
- Rapidly spreading vitiligo
- Lesions on areas known to be recalcitrant to therapy such as mucosal vitiligo
- Participants with a history of skin cancer
- Radiotherapy use
- Photosensitivity
- Women who are pregnant, breastfeeding or likely to become pregnant during the 9-month treatment period;
- Those currently using immunosuppressive drugs
- Involved in another clinical trial
- Not willing to participate
Key Trial Info
Start Date :
May 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05293119
Start Date
May 30 2022
End Date
November 30 2023
Last Update
March 24 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.